Tag: imaging

CARROLLTON, Texas, June 29, 2026 /PRNewswire/ -- Momentum Technologies ("Momentum"), a critical minerals refining and recovery company, today announced a series of milestones. Using...

PARIS, June 27, 2026 /PRNewswire/ -- The Qianhai Shenzhen-Hong Kong Youth Innovation and Entrepreneur Hub (Ehub) made its debut at Viva Technology (VivaTech) Paris 2026,...

LOS ANGELES, June 27, 2026 /PRNewswire/ -- Insta360 today announced the return of its annual Big Deal Days sales event, offering savings of up...

Five Years After Surfside, New Federal Findings Confirm What Structural Intelligence Could Have Prevented

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). 

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity...

MUNICH, June 25, 2026 /PRNewswire/ -- Dahua Technology, a world-leading video-centric AIoT solution and service provider, showcased its latest innovations for the renewable energy industry...

迈阿密, June 20, 2026 (GLOBE NEWSWIRE) -- 作为欧洲首只内存主题 ETF，Defiance ETFs 欣然宣布推出 Defiance Memory UCITS ETF (代码：DRAM)。 该基金旨在提供对从事半导体内存及数据存储系统开发、制造、商业化和存储业务相关公司的投资敞口。

邁阿密, June 20, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs 隆重宣佈推出歐洲首個記憶體 ETF——Defiance Memory UCITS ETF（股票代號：DRAM）。 此基金旨在讓投資者參與投資於記憶體半導體及數據儲存系統開發、製造、商業化及儲存等範疇的企業。

マイアミ発, June 20, 2026 (GLOBE NEWSWIRE) -- ディファイアンスETFs (Defiance ETFs) は、欧州初のメモリETFであるディファイアンス・メモリUCITS ETF (Defiance Memory UCITS ETF) (ティッカー: DRAM) のローンチを発表する。 本ファンドは、メモリ半導体およびデータストレージシステムの開発、製造、商品化、保管に携わる企業への投資機会の提供を目指す。

MIAMI, June 20, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs dengan sukacitanya mengumumkan pelancaran Defiance Memory UCITS ETF (kod dagangan: DRAM), iaitu ETF memori pertama di Eropah. Dana ini bertujuan untuk memberikan pendedahan kepada syarikat yang terlibat dalam pembangunan, pembuatan, pengkomersialan serta penyimpanan semikonduktor memori dan sistem storan data.